The Medicines Co. (MDCO) reported results from its Phase 3 trial of its intravenous antiplatelet cangrelor to oral clopidogrel in patients undergoing percutaneous coronary intervention on Sunday. Patients treated with cangrelor had a 22% reduced odds of experiencing the primary endpoint, which was a composite incidence of death, myocardial infarction, ischemia-driven revascularization or stent thrombosis at 48 hours after randomization.
The Medicines Co. gapped open higher Monday and is now up 1.30 at $33.00. The stock has risen above a 2 1/2 week range and has set a new high for the year.
For comments and feedback: editorial@rttnews.com